Table 2.
Observation (follow-up) time and time to event by outcomes of interest and treatment group.
| Observation time (days) | Time to event (days) | ||||||
| Outcome | Exposure | N | Mean (SD) | Median (Q1, Q3) | n | Mean (SD) | Median (Q1, Q3) |
| MI | All ARVs | 9500 | 394 (626) | 145 (59, 409) | 80a | 489 (622) | 243 (67, 690) |
| ATV | 1529 | 370 (598) | 144 (61, 363) | 8 | 363 (440) | 180 (46, 637) | |
| Non-ATV | 7971 | 399 (631) | 146 (59, 419) | 72 | 503 (640) | 250 (77, 690) | |
| Other PIs | 2053 | 279 (450) | 116 (51, 282) | 16 | 598 (821) | 249 (128, 821) | |
| NNRTI | 5307 | 459 (704) | 161 (61, 511) | 50 | 502 (610) | 256 (53, 701) | |
| INSTI | 611 | 276 (336) | 145 (66, 361) | 6 | 260 (223) | 233 (98, 345) | |
| Stroke | All ARVs | 9500 | 390 (622) | 144 (59, 404) | 170b | 403 (593) | 144 (28, 575) |
| ATV | 1529 | 367 (601) | 143 (60, 357) | 16 | 163 (215) | 72 (18, 280) | |
| Non-ATV | 7971 | 394 (626) | 144 (58, 416) | 154 | 428 (615) | 151 (31, 691) | |
| Other PIs | 2053 | 277 (451) | 113 (51, 281) | 34 | 249 (323) | 104 (31, 357) | |
| NNRTI | 5307 | 454 (698) | 160 (60, 509) | 105 | 521 (696) | 175 (37, 799) | |
| INSTI | 611 | 271 (326) | 144 (64, 360) | 15 | 186 (284) | 41 (8, 289) | |
| All-cause mortality | All ARVs | 9500 | 397 (630) | 147 (59, 413) | 190c | 501 (632) | 204 (70, 698) |
| ATV | 1529 | 373 (604) | 144 (61, 364) | 25 | 609 (864) | 127 (63, 894) | |
| Non-ATV | 7971 | 402 (635) | 147 (59, 428) | 165 | 484 (591) | 210 (71, 694) | |
| Other PIs | 2053 | 282 (455) | 116 (51, 284) | 37 | 410 (561) | 119 (55, 515) | |
| NNRTI | 5307 | 463 (708) | 164 (61, 516) | 118 | 523 (616) | 270 (88, 722) | |
| INSTI | 611 | 278 (339) | 146 (66, 365) | 10 | 302 (293) | 165 (84, 453) | |
N = number of patients in each treatment group; n = number of events in each treatment group. ARV, antiretroviral; ATV, atazanavir; INSTI, integrase strand transfer inhibitor; MI, myocardial infarction; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; Q1, first quartile; Q3, third quartile.
aA total of 8692 patients were censored due to a 30-day gap in medication and 728 were administratively censored at the end of study period.
bA total of 8627 patients were censored due to a 30-day gap in medication and 703 were administratively censored at the end of study period.
cA total of 8575 patients were censored due to a 30-day gap in medication and 735 were administratively censored at the end of study period.